Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6284-6288

  Su, Hong ^a   Yu, Liqin ^a   Nebbioso, Angela ^b   Carafa, Vincenzo ^b   Chen, Yadong ^a   Altucci, Lucia ^b   You, Qidong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anti proliferation; Anti tumor; HDAC inhibitors; Hydroxamic acid; N Hydroxybenzamide; Selectivity

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; BENZOHYDROXAMIC ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; ITF 2357; PANOBINOSTAT; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; KNOWLEDGE; LEUKEMIA CELL LINE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLONING, MOLECULAR; DRUG EVALUATION, PRECLINICAL; HELA CELLS; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; K562 CELLS; KINETICS; PROTEIN ISOFORMS; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

PUFFINUS AURICULARIS;

EID: 71049158815     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.100     Document Type: Article

References (17)

1. Marks P.A., Rifkind R.A., Richon V.M., and Breslow R. Clin. Cancer Res. 7 (2001) 759
2. Grant S., Easley C., and Kirkpatrick P. Nat. Rev. Drug Disc. 6 (2007) 21
3. Zhang Y., Fang H., Jiao J., and Xu W. Curr. Med. Chem. 15 (2008) 2840
4. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., and Brown R. Mol. Cancer. Ther. 2 (2003) 721
5. Fiskus W., Pranpat M., Bali P., Balasis M., Kumaraswamy S., Boyapalle S., Rocha K., Wu J., Giles F., Manley P.W., Atadja P., and Bhalla K. Blood 108 (2006) 645
6. Armeanu S., Pathil A., Venturelli S., Mascagni P., Weiss T.S., Gottlicher M., Gregor M., Lauer U.M., and Bitzer M. J. Hepatol. 42 (2005) 210
7. Itoh Y., Suzuki T., and Miyata N. Curr. Pharm. Des. 14 (2008) 529
8. Nielsen T.K., Hildmann C., Dickmanns A., Schwienhorst A., and Ficner R. J. Mol. Biol. 354 (2005) 107
9. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
10. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Luong C., Arvai A., Buggy J.J., Chi E., Tang J., Sang B.C., Verner E., Wynands R., Leahy E.M., Dougan D.R., Snell G., Navre M., Knuth M.W., Swanson R.V., McRee D.E., and Tari L.W. Structure 12 (2004) 1325
11. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkuhler C., and Di Marco S. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15064
12. Su H., Altucci L., and You Q. Mol. Cancer. Ther. 7 (2008) 1007
13. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., and Horinouchi S. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 87
14. Hildmann C., Wegener D., Riester D., Hempel R., Schober A., Merana J., Giurato L., Guccione S., Nielsen T.K., Ficner R., and Schwienhorst A. J. Biotechnol. 124 (2006) 258
15. Siliphaivanh P., Harrington P., Witter D.J., Otte K., Tempest P., Kattar S., Kral A.M., Fleming J.C., Deshmukh S.V., Harsch A., Secrist P.J., and Miller T.A. Bioorg. Med. Chem. Lett. 17 (2007) 4619
16. Jones P., Altamura S., Chakravarty P.K., Cecchetti O., De Francesco R., Gallinari P., Ingenito R., Meinke P.T., Petrocchi A., Rowley M., Scarpelli R., Serafini S., and Steinkuhler C. Bioorg. Med. Chem. Lett. 16 (2006) 5948
17. Chemical and physical data of compounds 1a-o are reported in Supplementary data.